Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06412055
Other study ID # NL85684.018.23
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 15, 2024
Est. completion date February 1, 2025

Study information

Verified date June 2024
Source Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact Merel-Anne Brehm, PhD
Phone + 3120 5664049
Email m.a.brehm@amsterdamumc.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this pilot study with a pre-post design is to investigate the effects of separate individualization of the AFO stiffness towards plantar- and dorsiflexion in a spring-hinged AFO on walking compared to a spring-like AFO (3 types) having the same stiffness in both directions. People with a neuromuscular disease or nerve injury causing at least plantarflexor weakness (determined as the inability to perform 3 single heel rises), with an indication for or using an AFO, will be fitted with a new, custom-made spring-hinged AFO with the NEURO SWING® system ankle joint (Fior& Gentz, Lüneburg In Duderstadt, Germany), of which the stiffness of ventral and dorsal compartment of this spring-hinged AFO will be individualized. For comparison, measurements will be performed with three different prefab spring-like AFOs with different stiffness levels (but which have a similar stiffness towards plantar and dorsiflexion), and the participants' current AFO if applicable, and shoes-only at baseline. The main outcome parameters will be the maximal ankle plantarflexion angle, ankle angular velocity and knee flexion angle during the loading response, which will be measured using a 3D gait analysis. Secondary outcomes include other gait biomechanics, walking energy cost, walking speed, standing balance, perceived physical functioning and perceived walking ability.


Description:

Many neuromuscular diseases cause weakness of the ankle dorsiflexors and plantarflexors, resulting in an altered gait pattern. In particular, weakness of the plantar flexors leads to a reduced walking ability as it hampers safety in both standing and walking. The primary treatment to improve walking ability and safety during standing and walking in dorsiflexor and/or plantarflexor weakness is the provision of ankle-foot orthoses (AFOs). To maximize treatment outcomes in case of lower leg weakness, the optimal AFO stiffness needs to be individually determined. Individual optimization of the stiffness can be performed with a spring-like AFO or with a spring-hinged AFO. With a spring-like AFO, the stiffness towards plantar- and dorsiflexion is similar, oftentimes resulting in a higher than necessary stiffness towards plantarflexion. An advantage of spring-hinged AFOs is that, unlike spring-like AFOs, the stiffness can be separately optimized in the directions of dorsiflexion and plantarflexion. The objective of this pilot study is to evaluate the effects of separate individualization of the AFO stiffness towards plantar- and dorsiflexion in a spring-hinged AFO compared to three types of spring-like AFO having the same stiffness in both directions on gait biomechanics, walking energy cost, walking speed, and standing balance. Additionally, effects will be evaluated of the optimal spring-hinged AFO 6 weeks after delivery of the AFO on perceived physical functioning, walking ability and satisfaction in daily life compared to the participants' AFO used at baseline if applicable or walking with shoes-only. In this pilot study with a pre-post design, people with a neuromuscular disease or nerve injury causing at least plantarflexor weakness with an indication for or using an AFO will be fitted with a new, custom-made spring-hinged AFO with the NEURO SWING® system ankle joint (Fior& Gentz, Lüneburg In Duderstadt, Germany). The stiffness of ventral and dorsal compartment of this spring-hinged AFO will be individualized using a previously developed optimization algorithm. The spring-hinged AFO with optimal stiffness settings will be used at home for 6-weeks. For comparison, the investigators will test the direct effects of three different prefab spring-like AFOs with different stiffness levels (but which have a similar stiffness towards plantar and dorsiflexion) of 2.8, 1.4 and 0.6 Nm/degrees respectively in a randomized order, and the participants' current AFO if applicable, and shoes-only at baseline.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date February 1, 2025
Est. primary completion date February 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age 18 years or older; 2. Presence of plantar flexor weakness in at least one leg, determined as a score lower than 5 on the manual muscle testing scale (Medical Research Council- MRC) and/or inability to perform three single heel rises, with or without dorsiflexion weakness; 3. Indicated for or using an AFO; 4. Ability to walk 6-minutes consecutively (with assistive device, if necessary). Exclusion Criteria: 1. When wearing the AFO, not able to walk short bouts of 10m without walking aids, such as a walker; 2. Foot deformities that do not fit in prefab spring-like AFOs; 3. Weakness of the knee extensor muscles, for which a knee-ankle-foot orthosis is indicated.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
NEURO SWING AFO (Fior& Gentz, Lüneburg In Duderstadt, Germany)
stiffness-optimized custom-made spring-hinged AFO with the NEURO SWING® system ankle joint build in
WalkOn Reaction® (Ottobock, Duderstadt)
comparator: prefab spring-like AFO without hinge with a predefined stiffness (2.8 Nm/degree).
Matrix Max2® (TruLife, Dublin, Ireland)
comparator: prefab spring-like AFO without hinge with a predefined stiffness (1.4 Nm/degree)
Matrix® (TruLife, Dublin, Ireland)
comparator: prefab spring-like AFO without hinge with a predefined stiffness (0.6 Nm/degree)

Locations

Country Name City State
Netherlands Department of rehabilitation medicine Amsterdam UMC, location AMC Amsterdam

Sponsors (2)

Lead Sponsor Collaborator
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) FIOR & GENTZ

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other number of participants with adverse events Adverse events are defined as any undesirable experience occurring to a subject during the study, whether or not considered related to the investigational product or experiments. The following adverse events reported spontaneously by the subject or observed by the investigator or his staff will be recorded; pressure sores, muscle soreness, pain, and falls. from baseline to 6 weeks post-delivery of the stiffness-optimized NEURO SWING AFO
Primary maximal ankle angular velocity in loading response in degrees measured during a 3D gait analysis day 0 (directly post-delivery)
Secondary maximal ankle angular velocity in loading response measured during a 3D gait analysis 6 weeks post-delivery for the stiffness-optimized NEURO SWING AFO
Secondary minimal ankle angle in loading response in degrees measured during a 3D gait analysis day 0 (directly post-delivery) and 6 weeks post-delivery for the stiffness-optimized NEURO SWING AFO only
Secondary ankle angle during midstance in degrees measured during a 3D gait analysis day 0 (directly post-delivery) and 6 weeks post-delivery for the stiffness-optimized NEURO SWING AFO only
Secondary maximal ankle angle during the stance phase in degrees measured during a 3D gait analysis day 0 (directly post-delivery) and 6 weeks post-delivery for the stiffness-optimized NEURO SWING AFO only
Secondary maximal ankle moment in Nm/kg measured during a 3D gait analysis day 0 (directly post-delivery) and 6 weeks post-delivery for the stiffness-optimized NEURO SWING AFO only
Secondary maximal ankle push-off power in Watt/kg measured during a 3D gait analysis day 0 (directly post-delivery) and 6 weeks post-delivery for the stiffness-optimized NEURO SWING AFO only
Secondary maximal knee flexion angle in loading response in degrees measured during a 3D gait analysis day 0 (directly post-delivery) and 6 weeks post-delivery for the stiffness-optimized NEURO SWING AFO only
Secondary minimal knee flexion angle during the stance phase in degrees measured during a 3D gait analysis day 0 (directly post-delivery) and 6 weeks post-delivery for the stiffness-optimized NEURO SWING AFO only
Secondary maximal external knee flexion moment in loading response in degrees measured during a 3D gait analysis day 0 (directly post-delivery) and 6 weeks post-delivery for the stiffness-optimized NEURO SWING AFO only
Secondary minimal external knee flexion moment during the stance phase in Nm/kg measured during a 3D gait analysis day 0 (directly post-delivery) and 6 weeks post-delivery for the stiffness-optimized NEURO SWING AFO only
Secondary maximal hip power during loading response in Watt/kg measured during a 3D gait analysis day 0 (directly post-delivery) and 6 weeks post-delivery for the stiffness-optimized NEURO SWING AFO only
Secondary maximal hip power during ankle push-off in Watt/kg measured during a 3D gait analysis day 0 (directly post-delivery) and 6 weeks post-delivery for the stiffness-optimized NEURO SWING AFO only
Secondary walking speed in m/s Walking speed will be measured during a 6-minute walk test (6MWT) at a self-selected comfortable speed. day 0 (directly post-delivery) and 6 weeks post-delivery for the stiffness-optimized NEURO SWING AFO only
Secondary walking energy cost in J/kg/m During a 6-minute walk test (6MWT) at comfortable speed, oxygen uptake (VO2) and carbon dioxide production (VCO2) will be measured using a breath-by-breath gas analysis system (K5, Cosmed, Rome, Italy) worn on the patient's back. Over at least one minute during the last three minutes of the test, walking energy cost will be calculated from these measured parameters and the comfortable walking speed. day 0 (directly post-delivery) and 6 weeks post-delivery for the stiffness-optimized NEURO SWING AFO only
Secondary velocity of center-of-pressure displacement in mm/s During the 3D gait analysis, a standing balance test will be performed. Participants will stand on one force plate with a standardised distance of 10 cm between the medial borders of the feet for 30 seconds. Standing posture, in terms of joint angles, will be determined using the markers placed according to the Plug-in-Gait model. Postural sway will be calculated as the Center-of-Pressure displacement during the last 15 seconds of the test. day 0 (directly post-delivery) and 6 weeks post-delivery for the stiffness-optimized NEURO SWING AFO only
Secondary center-of-pressure displacement in mm During the 3D gait analysis, a standing balance test will be performed. Participants will stand on one force plate with a standardised distance of 10 cm between the medial borders of the feet for 30 seconds. Standing posture, in terms of joint angles, will be determined using the markers placed according to the Plug-in-Gait model. Postural sway will be calculated as the Center-of-Pressure displacement during the last 15 seconds of the test. day 0 (directly post-delivery) and 6 weeks post-delivery for the stiffness-optimized NEURO SWING AFO only
Secondary Perceived walking ability Perceived walking ability in terms of satisfaction, intensity, safety and stability during walking will be measured on a 10-point Numerical Rating Scale (NRS) ranging from 0 (worst possible score) to 10 (best possible score). baseline and 6 weeks post-delivery of the stiffness-optimized NEURO SWING AFO
Secondary Perceived physical functioning Physical functioning will be measured using the physical functioning scale of the 36-item short form health survey (SF-36), with range 0-100 (a higher score means a better functioning). baseline and 6 weeks post-delivery of the stiffness-optimized NEURO SWING AFO
See also
  Status Clinical Trial Phase
Withdrawn NCT02235090 - Study of Feasibility to Reliably Measure Functional Abilities' Changes in Nonambulant Neuromuscular Patients Without Trial Site Visiting N/A
Completed NCT04411732 - Myotonia and Muscle Stiffness in NMD
Completed NCT00993161 - Upper Limb Evaluation in Non Ambulatory Patients With Neuromuscular Disorder N/A
Recruiting NCT02400528 - Prospective Cohort Follow-up of French Patients With Profound and Multiple Disabilities: Healthcare Pathways and Quality of Life Among Patients and Their Families N/A
Recruiting NCT01563705 - Prospective Follow-up of Patients With Glycogen Storage Disease Type III N/A
Completed NCT02780531 - Genetic and Blood Biomarkers in Neurological and Neuromuscular Diseases
Recruiting NCT02833168 - Screening Questionnaire for Respiratory Muscle Weakness and Sleep-disordered Breathing in Neuromuscular Disorders N/A
Withdrawn NCT01991535 - Response to NonInvasive Mechanical Ventilation According to the Breathing Pattern N/A